Literature DB >> 7671239

Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.

S Goto1, K Yoshida, T Morikawa, Y Urata, K Suzuki, T Kondo.   

Abstract

We studied the outward transport of cisplatin (CDDP)-glutathione (GSH) adduct (DDP-GSH) in CDDP-resistant cancer cells. Incubating the cells in the presence of CDDP resulted in the formation of an adduct with GSH and subsequent transport outside the cells. We used human colonic cancer cells sensitive (HCT8) and resistant (HCT8DDP) to CDDP and human ovarian cancer cells sensitive (A2780) and resistant (A2780DDP) to CDDP as materials. The concentration of intracellular GSH was higher in the resistant cells (118.7 +/- 5.9 nmol/10(6) HCT8DDP versus 19.0 +/- 1.0 nmol/10(6) HCT8 and 24.1 +/- 1.2 nmol/10(6) A2780DDP versus 9.4 +/- 0.5 nmol/10(6) A2780, respectively). The activity of the GSH-synthesizing enzyme, gamma-glutamylcysteine synthetase (gamma-GCS) was higher in the CDDP-resistant cells (7.1 +/- 0.2 milliunits/10(6) HCT8DDP versus 2.2 +/- 0.1 milliunits/10(6) HCT8 and 2.9 +/- 0.1 milliunits/10(6) A2780DDP versus 1.4 +/- 0.1 milliunits/10(6) A2780, respectively). Furthermore, immunological levels of gamma-GCS and the expression of gamma-GCS mRNA were higher in these CDDP-resistant cells than those in the control cells, in accordance with the change in the concentration of GSH. DDP-GSH transport increased in the CDDP-resistant colonic cancer cells by 219% (324 +/- 12 fmol/10(6) HCT8DDP cells/min versus 148 +/- 11 fmol/10(6) HCT8 cells/min) and the CDDP-resistant ovarian cancer cells by 126% (127 +/- 7 fmol/10(6) A2780DDP cells/min versus 101 +/- 8 fmol/10(6) A2780 cells/min). DDP-GSH transport was also estimated using inside-out vesicles from these cells. The active transport of DDP-GSH was 243% of HCT8 in HCT8DDP and 121% of A2780 in A2780DDP. These data suggest that the acquisition of CDDP resistance in cancer cells is due partly to the increase in the transport of DDP-GSH outside the cells as well as the increase in the concentration of GSH. Immunological estimation of the membrane proteins against human erythrocyte glutathione S-conjugate-stimulated Mg(2+)-ATPase sera resulted in no apparent cross-reactivity, suggesting that there are several transport systems for DDP-GSH.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671239

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.

Authors:  Toshifumi Yae; Kenji Tsuchihashi; Takatsugu Ishimoto; Takeshi Motohara; Momoko Yoshikawa; Go J Yoshida; Takeyuki Wada; Takashi Masuko; Kaoru Mogushi; Hiroshi Tanaka; Tsuyoshi Osawa; Yasuharu Kanki; Takashi Minami; Hiroyuki Aburatani; Mitsuyo Ohmura; Akiko Kubo; Makoto Suematsu; Kazuhisa Takahashi; Hideyuki Saya; Osamu Nagano
Journal:  Nat Commun       Date:  2012-06-06       Impact factor: 14.919

2.  Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae.

Authors:  K Grondin; A Haimeur; R Mukhopadhyay; B P Rosen; M Ouellette
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

3.  Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.

Authors:  Cynthia S Lancaster; Chaoxin Hu; Ryan M Franke; Kelly K Filipski; Shelley J Orwick; Zhaoyuan Chen; Zhili Zuo; Walter J Loos; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2010-09-21       Impact factor: 12.531

4.  Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.

Authors:  Ganna V Kalayda; Bart A J Jansen; Chris Molenaar; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2004-04-08       Impact factor: 3.358

5.  Genomic analysis reveals the biotechnological ability of Enterococcus italicus to produce glutathione.

Authors:  Francesca Borgo; Aristodemo Carpen; Chiara Ferrario; Stefania Iametti; Maria Grazia Fortina
Journal:  J Ind Microbiol Biotechnol       Date:  2013-03-05       Impact factor: 3.346

6.  Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.

Authors:  M J Welters; A M Fichtinger-Schepman; R A Baan; M J Flens; R J Scheper; B J Braakhuis
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.

Authors:  T Oguri; Y Fujiwara; T Isobe; O Katoh; H Watanabe; M Yamakido
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia.

Authors:  Shaloam R Dasari; Venkatramreddy Velma; Clement G Yedjou; Paul B Tchounwou
Journal:  Int J Cancer Res Mol Mech       Date:  2015-10-15

9.  miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

Authors:  Marijn T M van Jaarsveld; Patricia F van Kuijk; Antonius W M Boersma; Jozien Helleman; Wilfred F van IJcken; Ron H J Mathijssen; Joris Pothof; Els M J J Berns; Jaap Verweij; Erik A C Wiemer
Journal:  Mol Cancer       Date:  2015-11-17       Impact factor: 27.401

10.  Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines.

Authors:  S Okuno; H Sato; K Kuriyama-Matsumura; M Tamba; H Wang; S Sohda; H Hamada; H Yoshikawa; T Kondo; S Bannai
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.